Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: Down syndrome (DS), a major cause of mental retardation, is caused by trisomy of some or all of human chromosome 21 and includes three basic karyotypes: trisomy 21, translocation, and mosaicism. The derivation of DS-specific induced pluripotent stem cells (iPSCs) provides us novel DS models that can be used to determine the DS mechanism and to devise therapeutic approaches for DS patients. Methods: In the present study, fibroblasts from patients with DS of various karyotypes were reprogrammed into iPSCs via the overexpression of four factors: OCT4, SOX2, KLF4, and c-MYC, by using lentiviral vectors. The abilities of the iPSC-DS in the self-renewal and pluripotency in vitro and in vivo were then examined. Results: The iPSC-DS showed characteristics similar to those of human embryonic stem cells, particularly the morphology, surface marker (SSEA4, TRA-1-60, and TRA-1-81) expression, pluripotent-specific transcription-factor expression levels, and methylation status of the OCT4 promoter. The pluripotency of iPSC-DS was also tested in vitro and in vivo. Embryoid bodies were formed and showed the expression of differentiated markers for three germ layers. Furthermore, iPSC-DS formed classic teratomas when injected into nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice. Conclusions: iPSCs were generated from patients with DS. The iPSCs derived from different types of DS may be used in DS modeling, patient-care optimization, drug discovery, and eventually, autologous cell-replacement therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662 · cited 1×
“A number of studies have described successful derivation of iPSCs by using adenoviral vectors, episomal vectors, or the introduction of reprogramming proteins, synthetic modified mRNA [37-40], but a vectorfree protocol is usually limited by the low efficiency of iPSCs derivation.”
BackgroundHuman induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins
Zhou, H., Wu, S., Joo, J. Y., Zhu, S., Han, D. W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.04.005 · Cited by 1,788
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441 · cited 1×
“Recent studies showed that a variety of disease-specific iPSCs may be successfully produced [15-22].”
BackgroundSago, H., Carlson, E. J., Smith, D. J., Kilbridge, J., Rubin, E. M., Mobley, W. C., Epstein, C. J., & Huang, T.-T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6256 · Cited by 382 · cited 4×
“Although several types of DS mouse models, such as Ts65Dn [6,7] and Ts1Cje [8,9], are useful, the mouse model should have a phenotype that can be * Correspondence: yuema@ibp.”
BackgroundInfluentialPapapetrou, E. P., Tomishima, M. J., Chambers, S. M., Mica, Y., Reed, E., Menon, J., Tabar, V., Mo, Q., Studer, L., & Sadelain, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904825106 · Cited by 286 · cited 13×
“Activation of the promoters of hESC-specific genes in human iPSCs The DNA-methylation status of genomic DNA from iPSC-DS, parental HDFs, and H7 hESCs were analyzed to assess the epigenetic reprogramming of iPSC-DS [31].”
BackgroundMethodInfluentialDiscovery and genetic localization of down syndrome cerebellar phenotypes using the Ts65Dn mouse
Baxter, L. L. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.195 · Cited by 275
Olson, L. E., Roper, R. J., Baxter, L. L., Carlson, E. J., Epstein, C. J., & Reeves, R. H. (2004) · Developmental Dynamics · doi:10.1002/dvdy.20079 · Cited by 165 · cited 4×
“Although several types of DS mouse models, such as Ts65Dn [6,7] and Ts1Cje [8,9], are useful, the mouse model should have a phenotype that can be * Correspondence: yuema@ibp.”
BackgroundInfluentialEngineering a stem cell house into a home
Gilbert, P. M., & Blau, H. M. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt44 · Cited by 43
Cited by
Giobbe, G. G., Crowley, C., Luni, C., Campinoti, S., Khedr, M., Kretzschmar, K., De Santis, M. M., Zambaiti, E., Michielin, F., Meran, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13605-4 · Cited by 500
Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 299
Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia
Seo, J., Kritskiy, O., Watson, L. A., Barker, S. J., Dey, D., Raja, W. K., Lin, Y.-T., Ko, T., Cho, S., Penney, J., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0621-17.2017 · Cited by 156
In‐a‐dish: Induced pluripotent stem cells as a novel model for human diseases
Beltrão‐Braga, P. C. B., Pignatari, G. C., Russo, F. B., Fernandes, I. R., & Muotri, A. R. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22231 · Cited by 30
Metadata
- Authors
- Mou, X., Wu, Y., Cao, H., Meng, Q., Wang, Q., Sun, C., Hu, S., Ma, Y., & Zhang, H.
- Venue
- Stem Cell Research & Therapy
- Published
- 2012-04-18
- Volume
- 3
- Issue
- 2
- Pages
- 14-14
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2098354698
- Cited by
- 54
- References
- 10
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.